RT Journal Article SR Electronic T1 Myasthenia gravis: Frequently asked questions JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 103 OP 113 DO 10.3949/ccjm.90a.22017 VO 90 IS 2 A1 John A. Morren A1 Yuebing Li YR 2023 UL http://www.ccjm.org/content/90/2/103.abstract AB Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.